Therapeutic Asset Ratings
480 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Apalutamide
neoplasm
Helsinki University Central Hospital
P2
CC
(46)
Dfn-15
neoplasm
Emory University
P2
CC
(46)
Duloxetine
neoplasm
Yan Yang, MD, Ph.D
P2
CC
(46)
FLUTICASONE
Solid Tumor
Partner Therapeutics, Inc.
P2
CC
(46)
gw786034
neoplasm
Tianjin Medical University Second Hospital
P2
CC
(46)
hlx208
neoplasm
Shanghai Henlius Biotech
P2
CC
(46)
jyp0015
neoplasm
Guangzhou JOYO Pharma Co., Ltd
P2
CC
(46)
Palbociclib
neoplasm
Tianjin Medical University Second Hospital
P2
CC
(46)
PENTAPEPTIDE-1
neoplasm
Second Affiliated Hospital of Soochow University
P2
CC
(46)
prl3-zumab
neoplasm
Intra-IMMUSG Pte Ltd
P2
CC
(46)
Rec-4881
neoplasm
Recursion Pharmaceuticals Inc.
P2
CC
(46)
Sargramostim
neoplasm
Partner Therapeutics, Inc.
P2
CC
(46)
Tilsotolimod
neoplasm
Idera Pharmaceuticals, Inc.
P2
CC
(46)
TL118
neoplasm
Teligene US
P2
CC
(46)
Vebreltinib
neoplasm
Tianjin Medical University Second Hospital
P2
CC
(46)
ANTI-PD-1 MONOCLONAL ANTIBODY SYM021
neoplasm
Institut de Recherches Internationales Servier
P1
CC
(46)
Camonsertib
neoplasm
Memorial Sloan Kettering Cancer Center
P2
CC
(45)
Adebelimab
neoplasm
Shanghai Hengrui Pharmaceutical Co., Ltd.
P1/2
CC
(45)
Amxt1501
neoplasm
Aminex Therapeutics, Inc.
P1/2
CC
(45)
bs006
neoplasm
Binhui Biopharmaceutical Co., Ltd.
P1/2
CC
(45)
Decitabine
neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1/2
CC
(45)
lb1410
neoplasm
L & L Bio Co., Ltd., Ningbo, China
P1/2
CC
(45)
oh2
neoplasm
Binhui Biopharmaceutical Co., Ltd.
P1/2
CC
(45)
qlc1101
neoplasm
Qilu Pharmaceutical Co., Ltd.
P1/2
CC
(45)
rd14-01
neoplasm
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
P1/2
CC
(45)
Showing 101 to 125 of 480 assets
Previous
Page 5 of 20
Next
